Fig. 4From: A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumorsHumoral immune response against tumor-associated antigens (EpCam and Her2/neu) found in patient #4. Abbreviations: Appl, applicationBack to article page